| Anaemia | Blood and lymphatic system disorders | MedDRA 12.1 | Systematic Assessment | | - EG0000 affected37 at risk
- EG0011 affected38 at risk
|
| Leukocytosis | Blood and lymphatic system disorders | MedDRA 12.1 | Systematic Assessment | | - EG0000 affected37 at risk
- EG0013 affected38 at risk
|
| Leukopenia | Blood and lymphatic system disorders | MedDRA 12.1 | Systematic Assessment | | - EG0001 affected37 at risk
- EG0012 affected38 at risk
|
| Lymphopenia | Blood and lymphatic system disorders | MedDRA 12.1 | Systematic Assessment | | - EG0002 affected37 at risk
- EG0010 affected38 at risk
|
| Neutropenia | Blood and lymphatic system disorders | MedDRA 12.1 | Systematic Assessment | | - EG0000 affected37 at risk
- EG0013 affected38 at risk
|
| Thrombocytopenia | Blood and lymphatic system disorders | MedDRA 12.1 | Systematic Assessment | | - EG0002 affected37 at risk
- EG0011 affected38 at risk
|
| Cardiac failure congestive | Cardiac disorders | MedDRA 12.1 | Systematic Assessment | | - EG0001 affected37 at risk
- EG0010 affected38 at risk
|
| Tachycardia | Cardiac disorders | MedDRA 12.1 | Systematic Assessment | | - EG0000 affected37 at risk
- EG0011 affected38 at risk
|
| Ear congestion | Ear and labyrinth disorders | MedDRA 12.1 | Systematic Assessment | | - EG0000 affected37 at risk
- EG0011 affected38 at risk
|
| Ear pain | Ear and labyrinth disorders | MedDRA 12.1 | Systematic Assessment | | - EG0002 affected37 at risk
- EG0012 affected38 at risk
|
| Dry eye | Eye disorders | MedDRA 12.1 | Systematic Assessment | | - EG0001 affected37 at risk
- EG0010 affected38 at risk
|
| Eye irritation | Eye disorders | MedDRA 12.1 | Systematic Assessment | | - EG0001 affected37 at risk
- EG0010 affected38 at risk
|
| Eye pruritus | Eye disorders | MedDRA 12.1 | Systematic Assessment | | - EG0001 affected37 at risk
- EG0010 affected38 at risk
|
| Lacrimation increased | Eye disorders | MedDRA 12.1 | Systematic Assessment | | - EG0001 affected37 at risk
- EG0010 affected38 at risk
|
| Ocular hyperaemia | Eye disorders | MedDRA 12.1 | Systematic Assessment | | - EG0001 affected37 at risk
- EG0012 affected38 at risk
|
| Abdominal distension | Gastrointestinal disorders | MedDRA 12.1 | Systematic Assessment | | - EG0000 affected37 at risk
- EG0013 affected38 at risk
|
| Abdominal pain | Gastrointestinal disorders | MedDRA 12.1 | Systematic Assessment | | - EG0001 affected37 at risk
- EG0013 affected38 at risk
|
| Abdominal pain upper | Gastrointestinal disorders | MedDRA 12.1 | Systematic Assessment | | - EG0000 affected37 at risk
- EG0011 affected38 at risk
|
| Constipation | Gastrointestinal disorders | MedDRA 12.1 | Systematic Assessment | | - EG0002 affected37 at risk
- EG0013 affected38 at risk
|
| Diarrhoea | Gastrointestinal disorders | MedDRA 12.1 | Systematic Assessment | | - EG0003 affected37 at risk
- EG0019 affected38 at risk
|
| Dyspepsia | Gastrointestinal disorders | MedDRA 12.1 | Systematic Assessment | | - EG0001 affected37 at risk
- EG0013 affected38 at risk
|
| Flatulence | Gastrointestinal disorders | MedDRA 12.1 | Systematic Assessment | | - EG0000 affected37 at risk
- EG0012 affected38 at risk
|
| Gastrointestinal haemorrhage | Gastrointestinal disorders | MedDRA 12.1 | Systematic Assessment | | - EG0000 affected37 at risk
- EG0011 affected38 at risk
|
| Hyperchlorhydria | Gastrointestinal disorders | MedDRA 12.1 | Systematic Assessment | | - EG0001 affected37 at risk
- EG0010 affected38 at risk
|
| Lip pain | Gastrointestinal disorders | MedDRA 12.1 | Systematic Assessment | | - EG0001 affected37 at risk
- EG0010 affected38 at risk
|
| Mouth ulceration | Gastrointestinal disorders | MedDRA 12.1 | Systematic Assessment | | - EG0000 affected37 at risk
- EG0011 affected38 at risk
|
| Nausea | Gastrointestinal disorders | MedDRA 12.1 | Systematic Assessment | | - EG0007 affected37 at risk
- EG00114 affected38 at risk
|
| Odynophagia | Gastrointestinal disorders | MedDRA 12.1 | Systematic Assessment | | - EG0001 affected37 at risk
- EG0010 affected38 at risk
|
| Oedema mouth | Gastrointestinal disorders | MedDRA 12.1 | Systematic Assessment | | - EG0000 affected37 at risk
- EG0011 affected38 at risk
|
| Oral pain | Gastrointestinal disorders | MedDRA 12.1 | Systematic Assessment | | - EG0000 affected37 at risk
- EG0011 affected38 at risk
|
| Stomatitis | Gastrointestinal disorders | MedDRA 12.1 | Systematic Assessment | | - EG0001 affected37 at risk
- EG0010 affected38 at risk
|
| Vomiting | Gastrointestinal disorders | MedDRA 12.1 | Systematic Assessment | | - EG0000 affected37 at risk
- EG0015 affected38 at risk
|
| Asthenia | General disorders | MedDRA 12.1 | Systematic Assessment | | - EG0001 affected37 at risk
- EG0010 affected38 at risk
|
| Chest discomfort | General disorders | MedDRA 12.1 | Systematic Assessment | | - EG0002 affected37 at risk
- EG0010 affected38 at risk
|
| Chest pain | General disorders | MedDRA 12.1 | Systematic Assessment | | - EG0000 affected37 at risk
- EG0012 affected38 at risk
|
| Chills | General disorders | MedDRA 12.1 | Systematic Assessment | | - EG0006 affected37 at risk
- EG00116 affected38 at risk
|
| Fatigue | General disorders | MedDRA 12.1 | Systematic Assessment | | - EG0009 affected37 at risk
- EG00112 affected38 at risk
|
| Feeling abnormal | General disorders | MedDRA 12.1 | Systematic Assessment | | - EG0001 affected37 at risk
- EG0010 affected38 at risk
|
| Induration | General disorders | MedDRA 12.1 | Systematic Assessment | | - EG0000 affected37 at risk
- EG0011 affected38 at risk
|
| Influenza like illness | General disorders | MedDRA 12.1 | Systematic Assessment | | - EG0001 affected37 at risk
- EG0011 affected38 at risk
|
| Infusion related reaction | General disorders | MedDRA 12.1 | Systematic Assessment | | - EG0003 affected37 at risk
- EG0011 affected38 at risk
|
| Infusion site erythema | General disorders | MedDRA 12.1 | Systematic Assessment | | - EG0001 affected37 at risk
- EG0010 affected38 at risk
|
| Injection site discolouration | General disorders | MedDRA 12.1 | Systematic Assessment | | - EG0000 affected37 at risk
- EG0011 affected38 at risk
|
| Injection site erythema | General disorders | MedDRA 12.1 | Systematic Assessment | | - EG0000 affected37 at risk
- EG0019 affected38 at risk
|
| Injection site haematoma | General disorders | MedDRA 12.1 | Systematic Assessment | | - EG0000 affected37 at risk
- EG0011 affected38 at risk
|
| Injection site pain | General disorders | MedDRA 12.1 | Systematic Assessment | | - EG0000 affected37 at risk
- EG0016 affected38 at risk
|
| Injection site pruritus | General disorders | MedDRA 12.1 | Systematic Assessment | | - EG0000 affected37 at risk
- EG0018 affected38 at risk
|
| Injection site rash | General disorders | MedDRA 12.1 | Systematic Assessment | | - EG0000 affected37 at risk
- EG0012 affected38 at risk
|
| Injection site reaction | General disorders | MedDRA 12.1 | Systematic Assessment | | - EG0000 affected37 at risk
- EG0017 affected38 at risk
|
| Injection site swelling | General disorders | MedDRA 12.1 | Systematic Assessment | | - EG0000 affected37 at risk
- EG0011 affected38 at risk
|
| Localised oedema | General disorders | MedDRA 12.1 | Systematic Assessment | | - EG0000 affected37 at risk
- EG0011 affected38 at risk
|
| Oedema peripheral | General disorders | MedDRA 12.1 | Systematic Assessment | | - EG0002 affected37 at risk
- EG0016 affected38 at risk
|
| Pain | General disorders | MedDRA 12.1 | Systematic Assessment | | - EG0002 affected37 at risk
- EG0015 affected38 at risk
|
| Pyrexia | General disorders | MedDRA 12.1 | Systematic Assessment | | - EG0001 affected37 at risk
- EG0019 affected38 at risk
|
| Cytokine release syndrome | Immune system disorders | MedDRA 12.1 | Systematic Assessment | | - EG0000 affected37 at risk
- EG0012 affected38 at risk
|
| Drug hypersensitivity | Immune system disorders | MedDRA 12.1 | Systematic Assessment | | - EG0000 affected37 at risk
- EG0011 affected38 at risk
|
| Hypersensitivity | Immune system disorders | MedDRA 12.1 | Systematic Assessment | | - EG0001 affected37 at risk
- EG0013 affected38 at risk
|
| Cellulitis | Infections and infestations | MedDRA 12.1 | Systematic Assessment | | - EG0001 affected37 at risk
- EG0010 affected38 at risk
|
| Ear infection | Infections and infestations | MedDRA 12.1 | Systematic Assessment | | - EG0000 affected37 at risk
- EG0012 affected38 at risk
|
| Gastroenteritis | Infections and infestations | MedDRA 12.1 | Systematic Assessment | | - EG0000 affected37 at risk
- EG0011 affected38 at risk
|
| Herpes zoster | Infections and infestations | MedDRA 12.1 | Systematic Assessment | | - EG0000 affected37 at risk
- EG0011 affected38 at risk
|
| Influenza | Infections and infestations | MedDRA 12.1 | Systematic Assessment | | - EG0001 affected37 at risk
- EG0010 affected38 at risk
|
| Lower respiratory tract infection | Infections and infestations | MedDRA 12.1 | Systematic Assessment | | - EG0001 affected37 at risk
- EG0010 affected38 at risk
|
| Nasopharyngitis | Infections and infestations | MedDRA 12.1 | Systematic Assessment | | - EG0002 affected37 at risk
- EG0011 affected38 at risk
|
| Oral herpes | Infections and infestations | MedDRA 12.1 | Systematic Assessment | | - EG0000 affected37 at risk
- EG0013 affected38 at risk
|
| Rhinitis | Infections and infestations | MedDRA 12.1 | Systematic Assessment | | - EG0000 affected37 at risk
- EG0012 affected38 at risk
|
| Sinusitis | Infections and infestations | MedDRA 12.1 | Systematic Assessment | | - EG0001 affected37 at risk
- EG0010 affected38 at risk
|
| Tooth infection | Infections and infestations | MedDRA 12.1 | Systematic Assessment | | - EG0000 affected37 at risk
- EG0011 affected38 at risk
|
| Upper respiratory tract infection | Infections and infestations | MedDRA 12.1 | Systematic Assessment | | - EG0000 affected37 at risk
- EG0014 affected38 at risk
|
| Urinary tract infection | Infections and infestations | MedDRA 12.1 | Systematic Assessment | | - EG0000 affected37 at risk
- EG0011 affected38 at risk
|
| Face injury | Injury, poisoning and procedural complications | MedDRA 12.1 | Systematic Assessment | | - EG0000 affected37 at risk
- EG0011 affected38 at risk
|
| Procedural pain | Injury, poisoning and procedural complications | MedDRA 12.1 | Systematic Assessment | | - EG0000 affected37 at risk
- EG0011 affected38 at risk
|
| Alanine aminotransferase increased | Investigations | MedDRA 12.1 | Systematic Assessment | | - EG0001 affected37 at risk
- EG0010 affected38 at risk
|
| Aspartate aminotransferase increased | Investigations | MedDRA 12.1 | Systematic Assessment | | - EG0001 affected37 at risk
- EG0010 affected38 at risk
|
| Blood albumin increased | Investigations | MedDRA 12.1 | Systematic Assessment | | - EG0000 affected37 at risk
- EG0011 affected38 at risk
|
| Blood immunoglobulin g decreased | Investigations | MedDRA 12.1 | Systematic Assessment | | - EG0000 affected37 at risk
- EG0011 affected38 at risk
|
| Blood immunoglobulin m decreased | Investigations | MedDRA 12.1 | Systematic Assessment | | - EG0001 affected37 at risk
- EG0010 affected38 at risk
|
| Eosinophil count increased | Investigations | MedDRA 12.1 | Systematic Assessment | | - EG0000 affected37 at risk
- EG0011 affected38 at risk
|
| Platelet count increased | Investigations | MedDRA 12.1 | Systematic Assessment | | - EG0000 affected37 at risk
- EG0011 affected38 at risk
|
| White blood cell count decreased | Investigations | MedDRA 12.1 | Systematic Assessment | | - EG0000 affected37 at risk
- EG0012 affected38 at risk
|
| White blood cell count increased | Investigations | MedDRA 12.1 | Systematic Assessment | | - EG0000 affected37 at risk
- EG0011 affected38 at risk
|
| Anorexia | Metabolism and nutrition disorders | MedDRA 12.1 | Systematic Assessment | | - EG0001 affected37 at risk
- EG0013 affected38 at risk
|
| Decreased appetite | Metabolism and nutrition disorders | MedDRA 12.1 | Systematic Assessment | | - EG0000 affected37 at risk
- EG0012 affected38 at risk
|
| Hyperuricaemia | Metabolism and nutrition disorders | MedDRA 12.1 | Systematic Assessment | | - EG0001 affected37 at risk
- EG0010 affected38 at risk
|
| Hypocalcaemia | Metabolism and nutrition disorders | MedDRA 12.1 | Systematic Assessment | | - EG0000 affected37 at risk
- EG0011 affected38 at risk
|
| Hypokalaemia | Metabolism and nutrition disorders | MedDRA 12.1 | Systematic Assessment | | - EG0001 affected37 at risk
- EG0010 affected38 at risk
|
| Hypomagnesaemia | Metabolism and nutrition disorders | MedDRA 12.1 | Systematic Assessment | | - EG0001 affected37 at risk
- EG0012 affected38 at risk
|
| Arthralgia | Musculoskeletal and connective tissue disorders | MedDRA 12.1 | Systematic Assessment | | - EG0003 affected37 at risk
- EG0013 affected38 at risk
|
| Arthritis | Musculoskeletal and connective tissue disorders | MedDRA 12.1 | Systematic Assessment | | - EG0000 affected37 at risk
- EG0011 affected38 at risk
|
| Arthropathy | Musculoskeletal and connective tissue disorders | MedDRA 12.1 | Systematic Assessment | | - EG0000 affected37 at risk
- EG0011 affected38 at risk
|
| Back pain | Musculoskeletal and connective tissue disorders | MedDRA 12.1 | Systematic Assessment | | - EG0002 affected37 at risk
- EG0016 affected38 at risk
|
| Bone pain | Musculoskeletal and connective tissue disorders | MedDRA 12.1 | Systematic Assessment | | - EG0000 affected37 at risk
- EG0014 affected38 at risk
|
| Groin pain | Musculoskeletal and connective tissue disorders | MedDRA 12.1 | Systematic Assessment | | - EG0001 affected37 at risk
- EG0010 affected38 at risk
|
| Muscle spasms | Musculoskeletal and connective tissue disorders | MedDRA 12.1 | Systematic Assessment | | - EG0000 affected37 at risk
- EG0012 affected38 at risk
|
| Musculoskeletal chest pain | Musculoskeletal and connective tissue disorders | MedDRA 12.1 | Systematic Assessment | | - EG0000 affected37 at risk
- EG0011 affected38 at risk
|
| Musculoskeletal pain | Musculoskeletal and connective tissue disorders | MedDRA 12.1 | Systematic Assessment | | - EG0000 affected37 at risk
- EG0011 affected38 at risk
|
| Musculoskeletal stiffness | Musculoskeletal and connective tissue disorders | MedDRA 12.1 | Systematic Assessment | | - EG0000 affected37 at risk
- EG0011 affected38 at risk
|
| Myalgia | Musculoskeletal and connective tissue disorders | MedDRA 12.1 | Systematic Assessment | | - EG0002 affected37 at risk
- EG0015 affected38 at risk
|
| Neck pain | Musculoskeletal and connective tissue disorders | MedDRA 12.1 | Systematic Assessment | | - EG0001 affected37 at risk
- EG0010 affected38 at risk
|
| Pain in extremity | Musculoskeletal and connective tissue disorders | MedDRA 12.1 | Systematic Assessment | | - EG0001 affected37 at risk
- EG0012 affected38 at risk
|
| Pain in jaw | Musculoskeletal and connective tissue disorders | MedDRA 12.1 | Systematic Assessment | | - EG0001 affected37 at risk
- EG0010 affected38 at risk
|
| Akathisia | Nervous system disorders | MedDRA 12.1 | Systematic Assessment | | - EG0001 affected37 at risk
- EG0010 affected38 at risk
|
| Dizziness | Nervous system disorders | MedDRA 12.1 | Systematic Assessment | | - EG0001 affected37 at risk
- EG0017 affected38 at risk
|
| Dysgeusia | Nervous system disorders | MedDRA 12.1 | Systematic Assessment | | - EG0001 affected37 at risk
- EG0012 affected38 at risk
|
| Headache | Nervous system disorders | MedDRA 12.1 | Systematic Assessment | | - EG0008 affected37 at risk
- EG0019 affected38 at risk
|
| Lethargy | Nervous system disorders | MedDRA 12.1 | Systematic Assessment | | - EG0000 affected37 at risk
- EG0011 affected38 at risk
|
| Memory impairment | Nervous system disorders | MedDRA 12.1 | Systematic Assessment | | - EG0000 affected37 at risk
- EG0011 affected38 at risk
|
| Neuropathy peripheral | Nervous system disorders | MedDRA 12.1 | Systematic Assessment | | - EG0000 affected37 at risk
- EG0011 affected38 at risk
|
| Paraesthesia | Nervous system disorders | MedDRA 12.1 | Systematic Assessment | | - EG0001 affected37 at risk
- EG0010 affected38 at risk
|
| Restless legs syndrome | Nervous system disorders | MedDRA 12.1 | Systematic Assessment | | - EG0000 affected37 at risk
- EG0011 affected38 at risk
|
| Sinus headache | Nervous system disorders | MedDRA 12.1 | Systematic Assessment | | - EG0001 affected37 at risk
- EG0011 affected38 at risk
|
| Syncope | Nervous system disorders | MedDRA 12.1 | Systematic Assessment | | - EG0001 affected37 at risk
- EG0011 affected38 at risk
|
| Tension headache | Nervous system disorders | MedDRA 12.1 | Systematic Assessment | | - EG0001 affected37 at risk
- EG0010 affected38 at risk
|
| Anxiety | Psychiatric disorders | MedDRA 12.1 | Systematic Assessment | | - EG0000 affected37 at risk
- EG0011 affected38 at risk
|
| Depressed mood | Psychiatric disorders | MedDRA 12.1 | Systematic Assessment | | - EG0001 affected37 at risk
- EG0010 affected38 at risk
|
| Depression | Psychiatric disorders | MedDRA 12.1 | Systematic Assessment | | - EG0001 affected37 at risk
- EG0011 affected38 at risk
|
| Insomnia | Psychiatric disorders | MedDRA 12.1 | Systematic Assessment | | - EG0002 affected37 at risk
- EG0015 affected38 at risk
|
| Dysuria | Renal and urinary disorders | MedDRA 12.1 | Systematic Assessment | | - EG0001 affected37 at risk
- EG0010 affected38 at risk
|
| Micturition urgency | Renal and urinary disorders | MedDRA 12.1 | Systematic Assessment | | - EG0000 affected37 at risk
- EG0011 affected38 at risk
|
| Pollakiuria | Renal and urinary disorders | MedDRA 12.1 | Systematic Assessment | | - EG0000 affected37 at risk
- EG0011 affected38 at risk
|
| Vaginal haemorrhage | Reproductive system and breast disorders | MedDRA 12.1 | Systematic Assessment | | - EG0001 affected37 at risk
- EG0010 affected38 at risk
|
| Asthma | Respiratory, thoracic and mediastinal disorders | MedDRA 12.1 | Systematic Assessment | | - EG0000 affected37 at risk
- EG0011 affected38 at risk
|
| Cough | Respiratory, thoracic and mediastinal disorders | MedDRA 12.1 | Systematic Assessment | | - EG0002 affected37 at risk
- EG0015 affected38 at risk
|
| Dyspnoea | Respiratory, thoracic and mediastinal disorders | MedDRA 12.1 | Systematic Assessment | | - EG0002 affected37 at risk
- EG0015 affected38 at risk
|
| Dyspnoea exertional | Respiratory, thoracic and mediastinal disorders | MedDRA 12.1 | Systematic Assessment | | - EG0000 affected37 at risk
- EG0011 affected38 at risk
|
| Laryngeal oedema | Respiratory, thoracic and mediastinal disorders | MedDRA 12.1 | Systematic Assessment | | - EG0000 affected37 at risk
- EG0011 affected38 at risk
|
| Nasal congestion | Respiratory, thoracic and mediastinal disorders | MedDRA 12.1 | Systematic Assessment | | - EG0003 affected37 at risk
- EG0011 affected38 at risk
|
| Oropharyngeal pain | Respiratory, thoracic and mediastinal disorders | MedDRA 12.1 | Systematic Assessment | | - EG0005 affected37 at risk
- EG0013 affected38 at risk
|
| Postnasal drip | Respiratory, thoracic and mediastinal disorders | MedDRA 12.1 | Systematic Assessment | | - EG0001 affected37 at risk
- EG0010 affected38 at risk
|
| Productive cough | Respiratory, thoracic and mediastinal disorders | MedDRA 12.1 | Systematic Assessment | | - EG0000 affected37 at risk
- EG0011 affected38 at risk
|
| Rhinitis allergic | Respiratory, thoracic and mediastinal disorders | MedDRA 12.1 | Systematic Assessment | | - EG0000 affected37 at risk
- EG0011 affected38 at risk
|
| Rhinorrhoea | Respiratory, thoracic and mediastinal disorders | MedDRA 12.1 | Systematic Assessment | | - EG0001 affected37 at risk
- EG0012 affected38 at risk
|
| Sinus congestion | Respiratory, thoracic and mediastinal disorders | MedDRA 12.1 | Systematic Assessment | | - EG0000 affected37 at risk
- EG0011 affected38 at risk
|
| Throat irritation | Respiratory, thoracic and mediastinal disorders | MedDRA 12.1 | Systematic Assessment | | - EG0001 affected37 at risk
- EG0012 affected38 at risk
|
| Wheezing | Respiratory, thoracic and mediastinal disorders | MedDRA 12.1 | Systematic Assessment | | - EG0000 affected37 at risk
- EG0011 affected38 at risk
|
| Dermatitis | Skin and subcutaneous tissue disorders | MedDRA 12.1 | Systematic Assessment | | - EG0000 affected37 at risk
- EG0011 affected38 at risk
|
| Dry skin | Skin and subcutaneous tissue disorders | MedDRA 12.1 | Systematic Assessment | | - EG0000 affected37 at risk
- EG0012 affected38 at risk
|
| Erythema | Skin and subcutaneous tissue disorders | MedDRA 12.1 | Systematic Assessment | | - EG0000 affected37 at risk
- EG0015 affected38 at risk
|
| Hyperhidrosis | Skin and subcutaneous tissue disorders | MedDRA 12.1 | Systematic Assessment | | - EG0000 affected37 at risk
- EG0012 affected38 at risk
|
| Intertrigo | Skin and subcutaneous tissue disorders | MedDRA 12.1 | Systematic Assessment | | - EG0000 affected37 at risk
- EG0011 affected38 at risk
|
| Night sweats | Skin and subcutaneous tissue disorders | MedDRA 12.1 | Systematic Assessment | | - EG0000 affected37 at risk
- EG0012 affected38 at risk
|
| Photosensitivity reaction | Skin and subcutaneous tissue disorders | MedDRA 12.1 | Systematic Assessment | | - EG0000 affected37 at risk
- EG0011 affected38 at risk
|
| Pruritus | Skin and subcutaneous tissue disorders | MedDRA 12.1 | Systematic Assessment | | - EG0001 affected37 at risk
- EG0016 affected38 at risk
|
| Purpura | Skin and subcutaneous tissue disorders | MedDRA 12.1 | Systematic Assessment | | - EG0001 affected37 at risk
- EG0010 affected38 at risk
|
| Rash | Skin and subcutaneous tissue disorders | MedDRA 12.1 | Systematic Assessment | | - EG0001 affected37 at risk
- EG0011 affected38 at risk
|
| Skin hyperpigmentation | Skin and subcutaneous tissue disorders | MedDRA 12.1 | Systematic Assessment | | - EG0000 affected37 at risk
- EG0013 affected38 at risk
|
| Urticaria | Skin and subcutaneous tissue disorders | MedDRA 12.1 | Systematic Assessment | | - EG0001 affected37 at risk
- EG0013 affected38 at risk
|
| Flushing | Vascular disorders | MedDRA 12.1 | Systematic Assessment | | - EG0000 affected37 at risk
- EG0012 affected38 at risk
|
| Hot flush | Vascular disorders | MedDRA 12.1 | Systematic Assessment | | - EG0000 affected37 at risk
- EG0011 affected38 at risk
|
| Hypertension | Vascular disorders | MedDRA 12.1 | Systematic Assessment | | - EG0001 affected37 at risk
- EG0011 affected38 at risk
|
| Hypotension | Vascular disorders | MedDRA 12.1 | Systematic Assessment | | - EG0000 affected37 at risk
- EG0014 affected38 at risk
|
| Pallor | Vascular disorders | MedDRA 12.1 | Systematic Assessment | | - EG0000 affected37 at risk
- EG0011 affected38 at risk
|